R. ColemanLindsleyMDPhD

Hematologic Oncology

Instructor, Dana-Farber Cancer Institute

Dr. Lindsley is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2013
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2010
Washington University in St. Louis School of MedicineClass of 2008, M.D., Ph.D.

PubMed

20 citations
Single-cell multi-omics defines the cell-type-specific impact of splicing aberrations in human hematopoietic clonal outgrowths.
Mariela Cortés-López, Paulina Chamely, Allegra G Hawkins, Robert F Stanley, Ariel D Swett
Cell Stem Cell. 2023-09-07
46 citations
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages.
Simone Feurstein, Amy M Trottier, Noel Estrada-Merly, Matthew Pozsgai, Kelsey McNeely
Blood. 2022-12-15
9 citations
Transplant for TP53-mutated MDS and AML: because we can or because we should?
Jurjen Versluis, R Coleman Lindsley
Hematology. American Society of Hematology. Education Program. 2022-12-09

Abstracts/Posters

Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
R. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
R. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First RemissionClinically Relevant Abstract
R. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response
R. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Phase 1 Dose-Escalation Study of Adding Venetoclax to a Reduced Intensity Conditioning (RIC) Regimen Prior to Allogeneic Hematopoietic Cell Transplantation for Patie...
R. Coleman Lindsley, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all